UroGen Pharma (URGN) Accumulated Expenses (2016 - 2026)
UroGen Pharma's (URGN) quarterly Accumulated Expenses came in at $9.8 million in Q1 2026, up 41.19% YoY from $7.0 million in Q1 2025, and down 27.22% on a QoQ basis from $13.5 million in Q4 2025.
UroGen Pharma (URGN) Accumulated Expenses (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 11 years of Accumulated Expenses data on file, last reported at $9.8 million in Q1 2026.
- Quarterly Accumulated Expenses rose 41.19% year-over-year to $9.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.8 million (up 41.19% YoY) and the FY2025 annual result came in at $13.5 million, up 27.87% from the prior year.
- Accumulated Expenses slipped to $9.8 million in Q1 2026, from $13.5 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $13.5 million in Q4 2025 to a low of $4.9 million in Q1 2023.
- A 5-year average of $8.3 million and a median of $8.2 million in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses fell 5.09% — and 2025, when it jumped 70.04%.
- Tracing URGN's Accumulated Expenses over 5 years: stood at $8.3 million in 2022, then jumped by 30.97% to $10.8 million in 2023, then retreated by 2.26% to $10.6 million in 2024, then increased by 27.87% to $13.5 million in 2025, then decreased by 27.22% to $9.8 million in 2026.
- The last three Accumulated Expenses figures came in at $9.8 million (Q1 2026), $13.5 million (Q4 2025), and $11.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.25 Mn |
| Mar 31, 2026 | 9.84 Mn |
| Dec 31, 2025 | 13.52 Mn |
| Sep 30, 2025 | 11.11 Mn |
| Jun 30, 2025 | 11.65 Mn |
| Mar 31, 2025 | 6.97 Mn |
| Dec 31, 2024 | 10.57 Mn |
| Sep 30, 2024 | 9.03 Mn |
| Jun 30, 2024 | 6.85 Mn |
| Mar 31, 2024 | 4.99 Mn |
| Dec 31, 2023 | 10.81 Mn |
| Sep 30, 2023 | 8.15 Mn |
| Jun 30, 2023 | 6.72 Mn |
| Mar 31, 2023 | 4.92 Mn |
| Dec 31, 2022 | 8.26 Mn |
| Sep 30, 2022 | 6.63 Mn |
| Jun 30, 2022 | 6.43 Mn |
| Mar 31, 2022 | 5.15 Mn |
| Dec 31, 2021 | 6.95 Mn |
| Sep 30, 2021 | 6.48 Mn |